Objective The nature of model-based cost-effectiveness analysis can lead to disputes in the scientific community. We propose an iterative and collaborative approach to model development by presenting a flexible open-source simulation model for rheumatoid arthritis (RA), accessible to both technical and non-technical end-users. Methods The RA model is a discrete-time individual patient simulation with 6-month cycles. Model input parameters were estimated based on currently available evidence and treatment effects were obtained with Bayesian network meta-analysis techniques. The model contains 384 possible model structures informed by previously published models. The model consists of the following components: (i) modifiable R and C++ source code available in a GitHub repository; (ii) an R package to run the model for custom analyses; (iii) detailed model documentation; (iv) a web-based user interface for full control over the model without the need to be well-versed in the programming languages; and (v) a general audience web-application allowing those who are not experts in modeling or health economics to interact with the model and contribute to value assessment discussions. Results A primary function of the initial version of RA model is to help understand and quantify the impact of parameter uncertainty (with probabilistic sensitivity analysis), structural uncertainty (with multiple competing model structures), the decision framework (cost-effectiveness analysis or multi-criteria decision analysis), and perspective (healthcare or limited societal) on estimates of value. Conclusion In order for a decision model to remain relevant over time it needs to evolve along with its supporting body of clinical evidence and scientific insight. Multiple clinical and methodological experts can modify or contribute to the RA model at any time due to its open-source nature.
Introduction
Decision models can be used to inform efficient use of healthcare resources, but are only relevant when deemed credible by different stakeholders. They must also be representative of the local context and patient population of a particular decision maker.
The nature of model-based cost-effectiveness analysis (CEA) or value assessment, and the absence of a goldstandard model structure, can lead to disputes in the scientific community. Model inputs are typically informed by a formal evidence synthesis to ensure all relevant evidence is considered. However, decisions regarding the mathematical structure relating model inputs to outputs are frequently made without evaluating the impact of competing model structures on the ultimate findings. Disagreements are not easy to resolve because there is typically no public access to the actual models of published cost-effectiveness analyses.
This lack of transparency also poses problems for users whose perspective, local context, or patient population varies from that of the model developer, or for the incorporation of new clinical evidence. In the absence of public access to the actual model, varying key parameters or updating a CEA is cumbersome, if not impossible, for someone other than the original model developer. As a result, published costeffectiveness findings risk immediate irrelevance to some stakeholders and growing irrelevance to all stakeholders as new clinical evidence emerges.
Several authors have argued for open-source decision models for value assessment, but there are few real-world precedents and significant institutional barriers [1] [2] [3] . The typical cost-effectiveness model is complex. Thus, simply providing public access to the technical software code may not achieve the goal of transparency. Open-source models need to be accessible to both technical and non-technical stakeholders. A publicly available interface to interact with the open-source model allows non-technical stakeholders to 'pressure test' the model, be part of a dialogue regarding the credibility of the model, and perform analyses relevant for their local setting.
In this paper, we introduce the concept of an iterative collaborative approach to model development by presenting a flexible open-source simulation model using rheumatoid arthritis (RA) as an example use case, accessible to both technical and non-technical end users. The model can be used to estimate the value of alternative treatment sequences and evaluate the impact of parameter uncertainty (with probabilistic sensitivity analysis), structural uncertainty (with multiple competing model structures), the decision framework (CEA or multicriteria decision analysis [MCDA] ), and perspective (healthcare or limited societal) on estimates of value [4, 5] .
An Iterative Approach to the Development of Flexible Open-Source Models
The flexible open-source RA simulation model (IVI-RA model) is the first model released as part of the 'Open Source Value Project' (OSVP). A multi-stakeholder initiative, OSVP aims to maximize the relevance and credibility of value assessment in the decentralized US healthcare market by developing and providing access to flexible opensource decision models [6] . These interactive models have two primary objectives: (1) to enable a more constructive dialogue among stakeholders (e.g. patients, payers, providers, and manufacturers) with different beliefs about relevant clinical data, modeling approaches, and value perspectives; and (2) to provide local decision makers with means to credible value assessment that reflects their respective settings, incorporates the latest evidence, and accounts for different sources of scientific uncertainty (e.g. parameter or structural uncertainty due to gaps in evidence or different modeling beliefs).
In order for a decision model to remain relevant over time it needs to evolve along with its supporting body of clinical evidence and scientific insight. An open-source approach facilitates iterative development and collaboration among multiple clinical and methodological experts. We propose a four-step process for the development of flexible decision models for value assessment.
1. Release initial model to the public. The initial release of an OSVP model must be flexible and allow users to choose from a variety of plausible model structures and approaches based on clinical practice and previous modeling efforts. 2. Invite feedback and suggested improvements to the model through a public comment period. 3. Convene a technical expert panel to determine which of the evidence-based suggestions for improvement suggested in Step 2 should be implemented by means of peer review and a formal voting process. 4. Revise the model based on the feedback from the technical expert panel in
Step 3.
The four-step process is designed to be repeated multiple times so that the modeling approach and evidence considered can be refined over time. At the same time, other researchers in the scientific community can modify or contribute to the model at any time due to its open-source nature.
Modeling treatment for RA, a chronic autoimmune disorder causing pain, swelling, stiffness, and progressive joint damage, as an applied example of this method is well-suited to illustrate the OSVP approach. First, RA affects a relatively large portion (approximately 0.5-1.0%) of the population in developed countries and has a significant economic and quality-of-life impact [7] [8] [9] [10] . Second, RA is an area of significant innovation and there have been concerns over the high prices of treatments. There have been important advancements in the treatment of RA over the past decade and a total of 11 targeted therapies are now available, which suggests that there is an increasing need for tools to assess the cost effectiveness of these treatments [11] . Third, predicting disease progression is complex and there are a number of different measures of treatment response and morbidity [12] . Analyses have consequently been performed using different modeling approaches, and have reached different conclusions about the cost effectiveness of treatments for RA [11, [13] [14] [15] [16] [17] [18] [19] [20] [21] . Fourth, not only have new treatments come to market recently but evidence on existing RA treatments is growing rapidly from a variety of real-world data sources. Thus, there is a strong need for models that can be updated in a straightforward manner as the evidence base evolves.
To facilitate transparency, understanding, debate, and collaboration among diverse stakeholders, the IVI-RA model consists of the following publicly available components:
• Source code R and C ++ code for the model is available in an IVI GitHub repository Feedback can be incorporated into the model in one of two ways. First, comments on the scientific approach or evidence considered (Step 2) are reviewed by a technical expert panel that determines when they should be incorporated into the model (Step 3). Second, programmers may make changes to the code itself and issue a pull request on GitHub. Code changes that affect the scientific approach or evidence considered are only incorporated after a review by the technical expert panel, but bug fixes of performance improvements may be immediately accepted.
The Model

Purpose
The IVI-RA model is designed to assess the value of sequential treatment strategies for patients with moderate to severely active RA who did not respond to conventional disease-modifying antirheumatic drugs (cDMARDs) and are naive to biologic DMARDs (bDMARDs) or janus kinase/ signal transducers and activators of transcription (JAK/ STAT) inhibitors.
Since RA patients typically use multiple treatments over a lifetime, the model is capable of simulating a treatment sequence of arbitrary length. Treatments that can be included in a sequence include cDMARDs, bDMARDs, and JAK/STAT pathway inhibitors. The bDMARDs and JAK/ STAT inhibitors, which we refer to collectively as targeted DMARDs (tDMARDs), included in the current version of the model are tumor necrosis factor (TNF) inhibitors (etanercept, adalimumab, infliximab, certolizumab, golimumab), non-TNF inhibitors (abatacept, tocilizumab, rituximab), and JAK/STAT inhibitors (tofacitinib). At the end of a sequence, patients switch to non-biologic therapy (NBT), which encompasses a range of therapies that clinicians may feel is appropriate for all patients, such as methotrexate and sulfasalazine [19, 20] .
For each sequential treatment strategy evaluated, the model computes the following outcomes over a selected time horizon: progression of severity of disease over time according to the Health Assessment Questionnaire (HAQ) Disability Index score, time to treatment discontinuation, remaining life expectancy, quality-adjusted life-years (QALYs), healthcare sector costs (drug acquisition and administration costs, general management and monitoring costs, adverse event costs, hospitalization costs), and productivity losses.
Currently, two methodologies for decision analysis to evaluate competing strategies are supported by the model: CEA and MCDA. CEA compares relative cost and clinical effectiveness, while MCDA combines multiple criteria to aid decision making. In our CEA, value is measured using incremental cost per QALY gained expressed as the incremental net monetary benefit (INMB). In the MCDA, we follow the approach outlined by Thokala et al. and compute 'total value' by taking a weighted average of the values of six criteria translated onto a common scale [23] . The criteria, which were selected based on a review of the scientific literature and focus groups conducted among patients with RA, are as follows: (1) QALYs gained; (2) total healthcare sector costs; (3) productivity losses; (4) number of serious infections; (5) route of administration (oral/injection/infusion); and [6] time the medication has been on the market. In both the CEA and MCDA, value assessment can be performed from a healthcare sector perspective by only incorporating healthcare sector costs, or from a (limited) societal perspective by also including productivity losses.
Traditionally, the purpose of value assessment is to optimize health benefits with the available interventions for a certain disease state given the budget available [24] [25] [26] . However, the availability of an efficacious intervention for a certain disease state also provides some degree of protection against the physical and financial risk among healthy individuals at risk for the disease (i.e. 'insurance value') [27, 28] . The insurance value framework can be implemented with knowledge of two additional parameters beyond those in conventional CEA: the probability an individual develops a disease, and the rate at which consumers are willing to trade-off money in the sick state against money in the healthy state. The IVI-RA model allows users to incorporate insurance value into their analyses, while noting that this approach is less well-established than conventional CEA.
A primary role of this initial version of the IVI-RA model is to help understand and quantify the impact of parameter and structural uncertainty and value perspectives on the estimates of value for the intervention strategies compared. The model contains 384 possible model structures (see Online Appendix Table A1 ) informed by previously published models, and can be used to evaluate the implications of different modeling assumptions. In this paper, a topline overview of the model is provided. Additional information about the model and source data is available at https ://innov ation value initi ative .githu b.io/IVI-RA. We encourage readers to run custom analyses with the R package or web applications.
Model Structure
The IVI-RA model is a discrete-time individual patient simulation (IPS) with 6-month cycles that simulates the costs, health outcomes, and risks associated with treatments for individual patients in a given population. As depicted in Fig. 1 , treatments influence model outcomes indirectly through their impact on HAQ and adverse event rates. The HAQ affects direct healthcare sector costs, productivity, utility, and mortality, while adverse events affect direct healthcare sector costs and utility. In addition, since the model is an IPS, patient characteristics influence some model outcomes, namely HAQ, mortality, and utility.
Like most decision models in RA, the current version of the model simulates changes in disease severity using the HAQ [11, [13] [14] [15] [16] [17] [18] [19] [20] [21] . Figure 2 shows how the HAQ trajectory over time is modeled as a function of a sequence of treatments [13] [14] [15] . At the start of the simulation, each patient is assigned a baseline HAQ score. In the absence of treatment, HAQ increases (i.e. disease severity worsens), as depicted by the dashed line in Fig. 2 . For each treatment in a treatment sequence, treatment is separated into two distinct phases: an initial treatment phase of up to 6 months, consistent with data reported from randomized controlled trials (RCTs), and a maintenance phase thereafter until discontinuation. Clinical trial evidence suggests that during the initial treatment phase, HAQ declines sharply, and observational evidence suggests that HAQ remains relatively flat (with a potential slight decline) during the maintenance phase. Upon discontinuation of treatment, the HAQ score rebounds by a proportion of the improvement experienced during the initial 6-month period with that treatment.
Initial Treatment Phase
During the initial treatment phase, HAQ can be modeled as a change from baseline as a function of treatment according to three alternative structural relationships, as illustrated in Fig. 3 . The first option available in the model assumes treatment influences HAQ through its effect on the American College of Rheumatology (ACR) response criteria (labeled as H1: Treatment → ACR → HAQ), which is similar to the structure used in US-based cost-effectiveness models (e.g. Carlson et al. and Institute for Clinical and Economic Review) [11, 16] . ACR 20/50/70 response is defined as at least a 20/50/70% improvement in tender or swollen joint count, and at least three of the following five criteria: patient assessment, physician assessment, pain scale, functional status (typically the HAQ), visual analog pain scale, and erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) levels. The rationale for using ACR response rather than HAQ directly is that the evidence base relating treatment to ACR response is larger than the evidence base relating treatment to HAQ. The second available option to model the relationship between treatment and HAQ follows the National Institute for Health and Care Excellence (NICE) cost-effectiveness model, and models the effect of treatment on HAQ indirectly through its effect on ACR response and, in turn, the three categories of the European League Against Rheumatism (EULAR) response (no response, moderate response, or good response) [H2: Treatment → ACR → Treatment switching during the initial treatment phase can be modeled with six alternative structural pathways, as illustrated in Fig. 3 , labeled S1-S6. The first option follows a common approach where ACR non-responders discontinue treatment (S1: Treatment → ACR → Switch) [11, 16] . A drawback of this approach is that it is not consistent with current treat-to-target guidelines in the US, which are based on disease activity [29] . In S2-S5, treatment switching consequently depends on disease activity (remission, low, moderate, high) [30] . In S2-S4, ACR response predicts the change in disease activity from baseline, which, along with baseline disease activity, predicts absolute disease activity. Patients with moderate or high disease activity switch treatment, while patients with low disease activity or who are in remission continue treatment. Disease activity is measured using either the Disease Activity Score with 28-joint counts (DAS28) [S2: Treatment → ACR → DAS28 → Switch]; Simplified Disease Activity Index (SDAI) [S3: Treatment → ACR → SDAI → Switch]; or the Clinical Disease Activity Index (CDAI) [S4: Treatment → ACR → CDAI → Switch] [31] [32] [33] [34] . S5 is similar to S2-S4 but models the effect of treatment on changes in DAS28 directly, rather than indirectly through ACR response (Treatment → DAS28 → Switch). We also aimed to model the direct effect of treatment on SDAI and CDAI, but sufficient clinical trial data were not available. Finally, in the UK, since the British Society for Rheumatology and the British Health Professionals in Rheumatology recommend using the EULAR response, treatment switching in S6 depends on EULAR response (Treatment → ACR → EULAR → Switch). In particular, following the NICE model, EULAR non-responders are assumed to discontinue treatment, while moderate and good responders continue treatment [29] . Not all structural assumptions related to switching (S1-S6) can be used with each of the structural assumptions related to the impact of treatment on HAQ (H1-H3). The 12 possible combinations are outlined in Table 1 .
Estimates for effects of treatment on ACR, HAQ, and DAS28 for tDMARD-naive patients were based on a Bayesian network meta-analysis (NMA) of studies identified by means of a systematic literature review. ACR response was modeled using an order probit model, while changes in HAQ and DAS28 from baseline were modeled using a normal likelihood and an identity link. The models estimate absolute treatment effects for the reference group (cDMARDs) and treatment effects relative to cDMARDs for each tDMARD. Corresponding effects for tDMARD-experienced patients were obtained by multiplying these estimates with a constant factor based on evidence reported by Carlson et al. [16] . Estimates for the relationships between ACR, EULAR, and HAQ were based on the work of Aletaha and Smolen [35] , and Carlson et al. [16] , as well as the analysis by Stevenson   Fig. 3 During the initial treatment phase, HAQ as a function of treatment and treatment switching is modeled according to different structural modeling pathways (H1-H3, S1-S6). Disease activity refers to the DAS28, SDAI, or CDAI. H1-H3 represent structural modeling approaches of the impact of treatment on HAQ, and S1-S6 represent structural modeling approaches related to treatment switching (see text for more detail). ACR American College of Rheumatology, EULAR European League Against Rheumatism, HAQ Health Assessment Questionnaire, AEs adverse events, QALYs quality-adjusted lifeyears, DAS28 Disease Activity Score with 28-joint counts, SDAI Simplified Disease Activity Index, CDAI Clinical Disease Activity Index et al. [19] , using data from the US Veterans Affairs Rheumatoid Arthritis (VARA) registry and the British Society for Rheumatology Biologics Registers (BSRBR) database.
Maintenance Phase
In the maintenance phase, the long-term progression of HAQ can be modeled in two ways. First, as is common in CEA modeling of therapies for RA, HAQ is assumed to progress at a constant linear rate over time [14, 15] . Age-specific estimates of progression in the absence of tDMARDs were obtained from analysis of the National Data Bank (NDB) for Rheumatic Diseases longitudinal study by Wolfe and Michaud [36] and Michaud et al. [37] . Biologic-specific HAQ progression rates, as reported by Michaud et al., were used for tDMARDs in the model [37] . However, since emerging evidence suggests that the rate of HAQ progression is non-linear and varies across patients, our second scenario simulates HAQ progression using a latent class growth model (LCGM) with four distinct HAQ trajectories, and a rate of HAQ progression that decreases over time within each trajectory [38, 39] . As shown in Fig. 2 , upon discontinuation of treatment, the HAQ score rebounds toward its level at the start of treatment. In the absence of empirical data, we assume that the value of the rebound as a fraction of the initial decrease in HAQ during the first 6 months of treatment is 1 (uncertainty range 0.7-1).
The duration of the maintenance phase (i.e. time to discontinuation of maintenance treatment) is simulated using parametric time-to-event distributions. Discontinuation can either be due to serious infections alone or from all causes. If due to serious infections, time to discontinuation is drawn from an exponential distribution using the adverse event rates described below; if due to all causes, treatment duration depends on the choice of S1-S6. When S1 is used, the time to treatment discontinuation is simulated using a single timeto-event curve because we have been unable to find curves stratified by ACR response categories in the prior literature. Estimates for patients in the US are based on an analysis of the CORRONA database [40] . In contrast, when S2-S5 are selected, the time-to-event curves are a function of disease activity level, therefore patients with lower disease activity at the end of the initial treatment phase stay on treatment longer, on average. CORRONA survival curves are used to model treatment duration for patients with moderate disease activity. We adjusted this curve for patients in remission or with low disease activity using the odds ratios reported by Zhang et al. [41] Likewise, when structure S6 is used, the time-to-event distributions are stratified by EULAR response category based on analyses of the BSRBR database, and patients with good response at the end of the initial treatment phase tend to stay on treatment longer than patients with a moderate response [19] . In each case, time to discontinuation can be simulated using one of seven possible distributions: exponential, Weibull, Gompertz, gamma, log-logistic, lognormal, or generalized gamma.
Adverse Events
In line with the work of Stevenson et al., the adverse events included in the current version of the model are limited to serious infections; only serious infections are assumed to have a significant cost impact and increased risk over background rates to be meaningful to include [19, 42] . In accordance with Stevenson et al., serious infection rates with different tDMARDs are assumed to be equal, but different from cDMARDs, based on the NMA by Singh et al. [19, 43] . During the initial treatment phase, a patient immediately stops treatment if a serious infection occurs; during the maintenance phase, a serious infection occurs if the sampled time to a serious infection is shorter than the sampled time to treatment discontinuation. A patient can have, at most, one serious infection for each treatment in a treatment sequence.
Mortality
The probability of death is simulated as a function of age/ sex-specific mortality from US life tables, baseline HAQ, and changes in HAQ from baseline [44] . Wolfe et al. estimated an odds ratio of 2.22 for the effect of HAQ on mortality, which was applied to the absolute mortality rates of the general population (HAQ score of 0) to adjust mortality for RA patients as a function of baseline HAQ [45] . To capture the effect of treatment on mortality, each 0.25-unit increase in HAQ is assumed to increase subsequent 6-month mortality rates according to the hazard ratios reported by Michaud et al. [46] . 
Utility
Individual HAQ scores at a particular point in time are used to simulate the EuroQol five dimensions questionnaire (EQ-5D) utility scores (0-1 range), which in turn are used to simulate QALYs. However, since a number of different methods have been used to convert HAQ into utility, our model contains two different possible mapping algorithms. Our preferred algorithm is the Hernández Alava et al. mixture model, which uses a much larger sample size than other statistical models and has been shown to have better predictive accuracy [47] . Other algorithms are typically estimated using clinical trial data (e.g. Carlson et al. [16] and Stephens et al. [17] ) and consequently have more limited generalizability. The second utility algorithm available within the model is based on a linear regression analysis of real-world data by Wailoo et al. [48] , which has been used in a few previous CEAs (e.g. Wailoo et al. [15] and the Institute for Clinical and Economic Review [11] ). Serious infections also impact utility: a serious infection is assumed to decrease utility by 0.156 for the duration of the month of infection [19, 49] .
Costs
Healthcare sector costs considered in the model are related to drug acquisition and administration, serious infections, general management of RA, and hospitalization, while nonhealthcare sector costs are limited to work-related productivity loss. Drug acquisition costs are based on wholesale acquisition costs (WACs); users of the R package or web applications may also enter treatment-specific discounts (by default assumed to range from 20 to 30%), which reflect discounts and rebates from manufacturers. Administration costs are the cost of infusions for intravenous treatments. General management costs include costs related to physician visits, x-rays, tuberculosis tests, and outpatient follow-up, and do not vary across treatments [50, 51] . Costs of serious infections are assumed to equal the cost of a pneumonia hospitalization at Medicare reimbursements, or $5873. Annual hospitalization days and productivity losses are simulated as a function of HAQ [36] . Figure 4 describes the flow of a single patient through the simulation. The simulation runs for a patient's entire lifespan, beginning with treatment initiation and ending in death, or for a defined time horizon. The algorithm in the Online Appendix describes the main components of the IPS for a single patient and a single treatment. The full simulation cycles through each treatment in a treatment sequence, and through a representative sample of RA patients (see Table A2 in the Online Appendix).
Simulation
Parameter uncertainty is quantified using probabilistic sensitivity analysis (PSA), which propagates uncertainty in the model input parameters throughout the model by randomly sampling the input parameters from suitable probability distributions, which are reported in Table A3 in the Online Appendix [50, 52] . We use normal distributions for sample means, gamma distributions for right-skewed data, Dirichlet distributions for multinomial data, and uniform distributions when we lacked evidence on a parameter but wanted to specify lower and upper bounds. Multivariate normal distributions were used for regression models and to summarize Bayesian posterior distributions simulated using the Markov Chain Monte Carlo (MCMC) method.
The simulation of model outcomes proceeds in two steps. First, model parameters are sampled from their probability distributions, and, second, for each sampled parameter set and model structure of choice, expected values of model outcomes are computed by simulating multiple patients and subsequently averaging the simulated results. The number of simulated patients should be relatively large, so that credible intervals reflect uncertainty in the model parameter estimates, rather than random variability across simulated individuals. Model outcomes are aggregated to compute costs and QALYs for the CEA, as well as values of the MCDA criteria. Decision uncertainty is represented using various methods, including cost-effectiveness planes, cost-effectiveness acceptability curves, the cost-effectiveness acceptability frontier, and the expected value of perfect information.
Model Validation
A number of techniques were used to develop a credible model, including consultation with diverse stakeholders, careful statistical modeling, and leveraging best practices from software development. The extent to which the development and validation of the model is consistent with the Assessment of the Validation Status of Health-Economic decision models (AdViSHE) is assessed below [53] .
During development of the model, rheumatologists and patient representatives were consulted to inform the conceptual approach and R Shiny interface design. This feedback, combined with methodologies from prior models, informed the model development, the available model outcomes, and the presentation of results in the web applications. For instance, model structures in which treatment switching is a function of disease activity (DAS28, SDAI, or CDAI) were included because rheumatologists suggested that they would be consistent with US clinical guidelines. Moreover, feedback was elicited for uncertain input parameters with no available data, such as the magnitude of the HAQ rebound (assumed range 0.7-1). Finally, patients suggested that clinical (e.g. mortality, HAQ over time, adverse events) and economic outcomes (e.g. costs by category, productivity losses) should be explicitly separated from outcomes for CEA (e.g. incremental costs, incremental QALYs) and that treatment attributes such as mode of administration and years since US FDA approval should be incorporated into our MCDA.
When developing a decision model, model input parameter values may need to be estimated by analyzing empirical data. It is important to recognize that the choice of the statistical model used for parameter estimation can have an impact on the findings. In the IVI-RA model, the distribution of time to treatment discontinuation was estimated based on recreated Kaplan-Meier data from published sources using seven different parametric distributions. Selection of the most appropriate model was informed by the Akaike information criterion (AIC) and Bayesian information criterion (BIC), as well as visual inspection by comparing the parametric survival curves with the observed Kaplan-Meier curves. The generalized gamma distribution was selected as the default parametric distribution for modeling time to treatment discontinuation; however, alternative distributions can be used in the IVI-RA model.
An advantage of our open-source approach using R and GitHub is that it helps facilitate validation of the computer code. The R unit testing framework testthat is used to test the correctness of individual submodules that comprise the larger model. Each time a new code is pushed to GitHub, the continuous integration service travis-ci runs all unit tests, which ensures that the R package can be built without error. codecov.io is also run automatically and reports whether each line of R and C++ code is covered by the unit tests. Example unit tests include checking that random number generation from probability distributions at the C++ level match random number generation at the R level; that model outcomes are correctly bounded (e.g. HAQ between 0 and 3); and checking correct mappings between HAQ and costs. In the current version of the IVI-RA model, 89% of all lines of code have been tested. In addition to enhancing technical validity, unit testing and continuous integration make updating the model easier since new features can be added without worrying that unintended errors have been created in the existing code base. Since the entire code base is open source, users of either the R package or web interface can open issues on GitHub, highlighting bugs that need to be fixed or to make pull requests to directly modify the code themselves. The R Shiny interfaces facilitate testing of the face validity of the model by non-technical experts. We have tested a range of assumptions on input parameter values (e.g. assuming that there is no relationship between HAQ and morality or that drug prices are $0) and checked the face validity of model outcomes.
In general, the simulated model outcomes are consistent with both short-and long-term empirical data. For instance, unit tests confirm that simulated 6-month values of the proportion of patients in each ACR response category, the mean change in HAQ, and the mean change in DAS28 are equal to expected values based on parameter estimates from the NMA, with reasonable tolerance (e.g. difference < 0.01) for random variation. Furthermore, according to the simulation, a 55-year-old female (expected age at death of 83.7 years in the general population) with a baseline HAQ score of 1 will live to 77 years when HAQ does not increase over time, but that age at death decreases to 72.4 years if HAQ increases by 0.03 per year (approximate increase on cDMARDs). The latter estimate is consistent with research suggesting that RA reduces life expectancy by approximately 5-10 years [54] [55] [56] .
Finally, the simulated lifetime outcomes obtained with the IVI-RA model were compared with three other models (see Table A4 and Fig. 1a in the Online Appendix) used for US-specific cost-effectiveness evaluations. Specifically, estimated expected life-years, QALYs, and healthcare sector costs (all discounted at 3%) with adalilumab were compared. Separate simulations were performed so that population characteristics would match those in the comparison studies. To be consistent with the other models, changes in HAQ from baseline were assumed to have no impact on mortality. Healthcare sector costs were similar to the comparison studies and life-years were shorter. Life-years were shorter with the IVI-RA model because the odds ratio of mortality associated with baseline HAQ from Wolfe et al. implies a larger mortality risk for RA patients (especially as baseline HAQ increases) than from the mortality adjustments used in the other studies [45] . Furthermore, mean QALYs were considerably lower when the Hernández Alava utility algorithm was used instead of the Wailoo et al. algorithm [47, 48] .
Discussion
Structural Uncertainty
One of the key strengths of the IVI-RA model is that it captures multiple competing model structures and therefore facilitates structural uncertainty analysis (5). Figure 5 illustrates the variation in cost-effectiveness estimates for sequential biologic treatment (adalimumab + methotrexate followed by etanercept + methotrexate, abatacept + methotrexate, tocilizumab + methotrexate, tofacitinib + methotrexate, and rituximab + methotrexate) relative to conventional DMARD treatment with 32 of the available different model structures (see Table A5 in the Online Appendix for details). Likewise, assumptions related to mortality and the utility algorithm can have large impacts on absolute QALYs, which may translate to differences in incremental QALYs in cost-effectiveness analyses (Table A4 in the Online Appendix). These findings highlight the importance of additional research, debate, and collaboration to identify which model structures are appropriate and relevant, and when model averaging techniques should be used to properly capture structural uncertainty [57] . Statistical techniques for summarizing uncertainty analyses and estimating the expected value of partial perfect information (EVPPI) should be used to identify the parameters and model structures most likely to influence cost-effectiveness estimates and for which additional research would be most valuable [58, 59] .
Suggestions for Model Improvement
The current report primarily describes the initial version of the IVI-RA model. At the time of writing of this manuscript,
Step 2 (the public comment period) and Step 3 (feedback from the technical expert panel) of our four-step process for iterative model development had been completed. A summary report is available at http://www.theva luein itiat ive. org/wp-conte nt/uploa ds/2018/09/OSVP-IVI-RA-Model -v1.0-Proce ss-Summa ry_FINAL .pdf. During Step 2, a total of 159 comments were received from a diverse range of stakeholders, which included patient advocacy organizations, academics, physicians, non-profit organizations, and life-science companies. The suggestions for model improvement fell into five broad categories: model outcomes; model structure; treatment efficacy; evidence considered; and the value tool. Subsequently, a technical expert panel (n = 5; patient, rheumatologist, epidemiologist, and two health economists) determined which of the received suggestions should be implemented, by means of a modified Delphi process. Two rounds of surveys were administered using a web-based survey tool. The focus was on items that required rather extensive resources to implement (such as elaborate programming or additional evidence collection) or are likely to have a substantial impact on the findings of a model analysis. The following items were recommended as most important for the next iteration of the model: including triple therapy, sarilumab, and biosimilars; modeling the time to discontinuation of maintenance treatment conditional on HAQ or disease activity during the maintenance phase rather than 6-month response; incorporating additional utility algorithms; and estimating long-term treatment effects with additional data sources.
In addition to these recommendations for the next iteration of the IVI-RA model, future work on the model should also focus on improving estimates for parameters that are the most likely to drive the result but are based on limited Fig. 5 Sensitivity of the cost-effectiveness estimate of sequential biologic treatment versus conventional DMARD treatment with 32 competing structural assumptions. a Average incremental net-monetary benefit at a willingness-to-pay of US$150,000; b probability that sequential biologic treatment is cost effective given parameter uncertainty in the estimates. DMARD disease-modifying antirheumatic drug data. Although the effects of tDMARDs on ACR response and HAQ at 6 months are critical parameters, we only had access to aggregate-level data obtained from publications of relevant RCTs. Unfortunately, the available information did not allow estimating stable relative treatment effects for all tDMARDs of interest among tDMARD-experienced patients. Furthermore, the treatment effect likely does not only depend on whether a patient is tDMARD-naive or -experienced but also on the number of previous failures, and potentially based on the type of prior tDMARD received. Beyond treatment history, other patient characteristics may also impact treatment effects, which are currently ignored. Future analyses based on patient-level data of the relevant RCTs are needed to incorporate heterogeneous treatment effects into the model. The same can be said for treatment discontinuation during the maintenance phase. Direct analyses of databases with patient-level data, such as CORRONA or the NDB for Rheumatic Diseases, could generate more accurate estimates of treatment duration, as well as the effect of treatment response or disease activity level on discontinuation rates.
Although a non-linear model can be used to model HAQ progression for patients using cDMARDs or receiving NBT, we only have estimates of constant linear progression of HAQ for patients taking tDMARDs. Future studies that use non-linear mixture models to estimate the long-term progression of disease for patients using tDMARDs are needed.
An important predictor of cost effectiveness is the degree to which the HAQ score increases following treatment failure. Most models currently assume that the HAQ score increases by the same amount as the initial 6-month decline in the HAQ score, but there is little evidence to support this. Empirical data to quantify the rebound effect are critical given the current structures available with the model.
Finally, the current model does not account for adverse events other than serious infections, even though other types of adverse events may be important to patients and can result in treatment switching. Furthermore, the model allows the serious infection rate to differ between cDMARDs and tDMARDs, but assumes that the infection rate is equal among tDMARDs. Future model versions might want to reconsider the evidence underlying this assumption.
Experience with the Open-Source Approach to Model Development to Date
While we believe that an open-source and collaborative approach can improve value assessment, it is not without challenges. First, although we are of the opinion that it is one of the strengths of the OSVP, an approach that elicits input from a variety of stakeholders is inherently challenging because it requires communication from experts from diverse backgrounds. For instance, it was more challenging than we expected for methodological experts to understand feedback from clinicians and for clinicians to understand the implications of methodological assumptions in the model. This difficulty was present both when developing the model and for the technical expert panel when reviewing the public comments and recommendations for model improvement. Second, decision models can be complex and may require considerable mathematical sophistication and time to understand, which makes commenting on the model (Step 2) a labor-intensive process and communicating the model to stakeholders challenging. To date, we have received thoughtful comments during our first public comment period, but recognize that considerable efforts must be made to encourage engagement from relevant organizations and researchers moving forward. The barriers for contributing to the code base itself are even larger, given that they require mathematical and programming expertise in addition to an interest in a particular disease space (e.g. RA). While one of the purposes of the OSVP is to enhance the credibility and adaptability of decision models for use in real-world decision making, their complexity can make crowd sourcing of expertise more challenging than anticipated.
Third, developing an open-source model, particularly one that accounts for structural uncertainty, is a time-consuming process. Open-source code should be well-documented and well-tested, which takes additional resources. Moreover, open-source models are never truly finished, unlike models developed for a single publication. Open-source developers must fix bugs and respond to pull requests, and, as we argue, update models over time as the evidence base evolves.
Despite these challenges, we believe that the benefits of a collaborative and transparent approach are worth the effort and that steps can be taken to mitigate the challenges. The various components of our approach allow for different layers of accessibility whereby some users can go so far as to inspect the raw underlying C++ code while others may simply want to interact with the web applications. We created the web interfaces precisely to help translate complex concepts into simpler terms and to facilitate communication between experts from diverse backgrounds. The IVI-RA Model Interface is designed for health economists and modelers who might not want to use the R package for all analyses, and the IVI-RA Value Tool is aimed at making the model accessible to less technical stakeholders. To make the Value Tool as relevant as possible, we conducted a number of user interviews with clinicians and patients, although we recognize that creating relevant web applications is an evolving process, especially for use by local decision makers. Furthermore, additional incentives are needed for the development of open-source software. Currently, academic researchers are rewarded primarily for academic publications, even though open-source software can have enormous benefits for an entire community of researchers and other stakeholders. Rewards such as grants or credit toward tenure and promotion for software development and open science more generally would help.
Conclusions
The IVI-RA model developed as part of the OSVP is designed to overcome the limitations of traditional approaches to model-based value assessment in the context of the US decentralized decision-making environment: limited transparency, lack of flexibility to perform analyses representative of the local setting, difficult to update, and insufficient quantification of uncertainty. The IVI-RA model is an open-source model written in R and C++, with different web interfaces to allow technical and non-technical stakeholders to interact with the model. It enables a more constructive dialogue between patients, payers, providers, policymakers, and manufacturers with different beliefs about relevant clinical data, modeling approaches, and value perspectives. The model facilitates iterative development and collaboration between multiple clinical and methodological experts with the ultimate aim of having a transparent model useful and acceptable for many stakeholders, and therefore provides local decision makers with means to credible value assessment that reflects the local setting and is based on the latest evidence while striving to account for all scientific uncertainty.
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